PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas
There is an urgent clinical need for new therapeutic regimens for the effective treatment of advanced sarcomas. Accumulating evidence suggests that programmed death receptor-1/programmed death protein ligand-1 (PD-1/L1) inhibitors have synergistic effects with chemotherapy and have been approved for...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Jezik: | English |
| Izdano: |
Frontiers Media S.A.
2022-08-01
|
| Serija: | Frontiers in Immunology |
| Teme: | |
| Online dostop: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.898255/full |